Adam Mcananey Sells 9,092 Shares of Oscar Health (NYSE:OSCR) Stock

Key Points

• Oscar Health insider Adam Mcananey sold 9,092 shares at an average price of $31.45, generating $285,943. The transaction was conducted under a Rule 10b5-1 plan to cover tax withholding, reducing his holdings by 4.17%.
• Oscar Health shares rose 2.0% to $32.90, near the company’s 52-week high of $33.55. The insurer reported quarterly EPS of $1.10 versus the $0.40 consensus estimate, while revenue increased 70.4% year over year to $4.88 billion.
• Institutional investors own approximately 75.7% of Oscar Health, while analysts maintain a consensus “Hold” rating with an average price target of $26.22—below the current share price.

Oscar Health, Inc. (NYSE:OSCR - Get Free Report) insider Adam Mcananey sold 9,092 shares of the firm's stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total transaction of $285,943.40. Following the sale, the insider owned 209,004 shares in the company, valued at approximately $6,573,175.80. This trade represents a 4.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oscar Health Trading Up 2.0%

OSCR traded up $0.65 during trading on Tuesday, hitting $32.90. The company's stock had a trading volume of 4,754,751 shares, compared to its average volume of 7,062,275. The firm's 50 day moving average price is $30.49 and its 200-day moving average price is $22.87. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.09 and a quick ratio of 1.09. The stock has a market cap of $10.15 billion, a PE ratio of 23.50, a PEG ratio of 0.66 and a beta of 2.37. Oscar Health, Inc. has a twelve month low of $10.69 and a twelve month high of $33.55.

Oscar Health (NYSE:OSCR - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.70. The business had revenue of $4.88 billion for the quarter, compared to analysts' expectations of $4.73 billion. Oscar Health had a return on equity of 38.45% and a net margin of 3.60%.The business's revenue was up 70.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.89) earnings per share. On average, analysts expect that Oscar Health, Inc. will post 1.54 earnings per share for the current year.

Institutional Trading of Oscar Health

A number of institutional investors have recently modified their holdings of OSCR. T. Rowe Price Investment Management Inc. increased its position in Oscar Health by 11.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,217,816 shares of the company's stock worth $132,461,000 after purchasing an additional 910,320 shares in the last quarter. California State Teachers Retirement System grew its stake in Oscar Health by 3,214.2% during the second quarter. California State Teachers Retirement System now owns 7,803,043 shares of the company's stock worth $222,543,000 after buying an additional 7,567,600 shares during the period. Morgan Stanley grew its stake in Oscar Health by 42.8% during the fourth quarter. Morgan Stanley now owns 6,814,046 shares of the company's stock worth $97,918,000 after buying an additional 2,043,758 shares during the period. Thrive Capital Management LLC increased its position in shares of Oscar Health by 33.4% in the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company's stock worth $85,258,000 after acquiring an additional 1,588,395 shares in the last quarter. Finally, BIT Capital GmbH raised its stake in shares of Oscar Health by 545.0% in the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company's stock valued at $88,897,000 after acquiring an additional 5,227,152 shares during the period. Hedge funds and other institutional investors own 75.70% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the company. Wall Street Zen upgraded Oscar Health from a "buy" rating to a "strong-buy" rating in a report on Sunday, June 14th. UBS Group raised their target price on shares of Oscar Health from $20.00 to $26.00 and gave the stock a "neutral" rating in a research report on Friday, August 7th. The Goldman Sachs Group restated a "neutral" rating and issued a $30.00 target price on shares of Oscar Health in a report on Tuesday, August 11th. Piper Sandler reaffirmed an "overweight" rating and set a $36.00 price target on shares of Oscar Health in a research note on Tuesday, July 28th. Finally, Zacks Research upgraded shares of Oscar Health from a "hold" rating to a "strong-buy" rating in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Oscar Health presently has an average rating of "Hold" and an average target price of $26.22.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company's primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.